Abstract 4082
Background
EGFR-TKIs are the preferred 1L therapy for pts with EGFRm metastatic NSCLC. However, treatment and survival in this population with 2L therapy and beyond are not well defined in the RW setting. To address this, we analysed RW cohort data in the USA, UK, Germany and France.
Methods
A retrospective chart review was conducted for 472 pts with EGFRm NSCLC receiving a 1L 1G / 2G EGFR-TKI (1 Jan 2015–31 Dec 2017). Data on 1L and 2L treatment and progression after 1L initiation (defined by clinical progression, start of 2L treatment or death before 2L treatment initiation) were extracted. 1L progression-free (PFS) and overall survival (OS) were estimated via Kaplan–Meier methods.
Results
Baseline characteristics at 1L: median age 62 yrs; 43% female; 61% current/former smokers; 60% Caucasian; 76% Exon 19 deletion. 1L EGFR-TKI treatments: 44% afatinib; 36% erlotinib; 21% gefitinib. Median duration of overall follow-up from start of 1L was 19.9 months (mo; range 0.3–50.3). Of 472 pts, 344 (73%) progressed on 1L treatment, including 158 who died during follow-up. 128 (27%) pts did not progress: 86 (18%) remained on 1L treatment and 42 (9%) pts discontinued 1L treatment before follow-up end. Median 1L PFS (95% CI) was 14.5 (13.3, 15.6) mo and median OS (95% CI) from start of 1L was 34.6 (29.5, 45.5) mo. Of 344 pts with 1L progression, 255 (74%) were tested for T790M; 129 (38%) were positive, of whom 97 received osimertinib (75%). Of 126 pts testing negative, 17 (13%) received osimertinib. Of 344 pts with 1L progression, 258 (75%) received 2L treatment, osimertinib-containing regimens being most common (n = 109/258, 42%). For 86 (25%) pts with 1L progression but no 2L treatment, 73 (85%) died and 13 (15%) were alive at follow-up end.
Conclusions
25% of pts progressing on 1L EGFR-TKIs did not receive 2L treatment (due to death in most cases). Furthermore, 25% of pts who progressed on 1L treatment and tested T790M positive did not receive osimertinib. Findings indicate that rates of resistance mutation testing and utilisation of effective EGFRm NSCLC therapies may be suboptimal.
Clinical trial identification
Editorial acknowledgement
Robert Harrison, PhD, of iMed Comms, Macclesfield, UK, an Ashfield Company; funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
R. Shah: Honoraria (self), Travel / Accommodation / Expenses: Boehringer Ingelheim, Roche, AstraZeneca. N. Girard: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): AstraZeneca, Boehringer Ingelheim. S.P. Nagar: Advisory / Consultancy, Employee of RTI-HS who provides consulting services to AstraZeneca: AstraZeneca. F. Griesinger: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Celgene, Lilly, Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, Takeda, Siemens; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AbbVie. J. Roeper: Honoraria (institution): Boehringer Ingelheim, Roche, AstraZeneca. K. Davis: Research grant / Funding (institution): AstraZeneca, Novartis, Celgene, Sanofi, Pfizer, Amgen. N. Bakker: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. B. Thakrar: Full / Part-time employment: AstraZeneca. A. Taylor: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest. J. Feliciano: Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: Eli Lilly.
Resources from the same session
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract
4325 - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract